🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Now that the lab has stuff in it, I’m looking for a postdoc. Must have: - Mouse experience (several years ideally) - Cell culture experience - An interest in T cells - Team player Bonus points for: - any flow experience - any scRNAseq exp (wet or dry) - CAR T manufacturing

1/ Why is Ki-67 called Ki-67? And why am I attaching a photo of this beautiful city to the tweet? If you work in pathology or oncology, you’ve likely come across Ki-67 many times. But where does the name come from? A short 🧵 on the origins, function, and significance of Ki-67.

7/ So what does it actually do? Chromatin organization during mitosis: Ki-67 coats the surface of condensed chromosomes, forming a perichromosomal layer, like a protective shell. It prevents chromosomes from clumping together. Think of it as a chromosomal surfactant.

And the great companion Blood Cancer Journal piece to ours is now out too - should all non-infectious diarrhea after CAR-T for myeloma be presumed to be enteric T-cell lymphoma? They suggest yes, we suggest no... either way, we need better diagnostic tools! nature.com/articles/s4140…

Nice adjusted comparison of CARTITUDE-4 data by Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 et al - Dara-Kd is control arm in iMMagine-3 (anito-cel) but not CARTITUDE-4 or KarMMa-3... Obviously not the same as RCT, but - compared to matched CANDOR data - cilta-cel certainly has the edge! link.springer.com/article/10.100…

What are some risk factors associated with delayed neurotoxicity in patients with R/R #myeloma treated with cilta-cel? Yi Lin of Mayo Clinic shared the findings of a real-world analysis investigating this at #EHA2025: 🎥 ow.ly/T2VS50WfWjJ #CARTCell #ImmunoOnc #MMSM

We are getting used to monthly approval of "something" for myeloma - Yelak Biru Rahul Banerjee, MD, FACP oncodaily.com/blog/325210 #OncoDaily #Oncology #Cancer #Health #Medicine #Myeloma

Hi friends, it's #Myeloma Monday! Here are Top Posts of the Week 🎉🎉🎉 1/ Ben Derman on in-vivo CAR Ts for myeloma: x.com/bdermanmd/stat…

Ben Derman 2/ Al-Ola A Abdallah MD (USMIRC) on tocilizumab prophylaxis for patients with #MMsm treated with bispecific antibodies: x.com/Abdallah81MD/s…

Ben Derman Al-Ola A Abdallah MD (USMIRC) 3/ Rahul Banerjee, MD, FACP with more on in-vivo BCMA CAR in myeloma: x.com/RahulBanerjeeM…

4/ Mostafa Faisal on IEC-associated enterocolitis following CAR-T therapy: x.com/MostafaFaisal1…

Mostafa Faisal 5/ Robert Z. Orlowski with the #Myeloma Paper of the Day: x.com/Myeloma_Doc/st…

I think we have to be cautious. For all rare complications of CART (inc. Parkinson’s) our understanding of pathophys. is still at infancy. - Diagnostic accuracy has to improve - Need prospective data collection registries to know true denominator, clinical course - Knowing this

Don't miss your chance to ask YOUR questions LIVE on Sat. 7/19 @ 10:15am PST! IMF CMO Joseph Mikhael, SparkCures founder Brian McMahon, & myeloma patient advocate Thomas Goode break down #myeloma clinical trials in this 30-min power session. RSVP: mmsm.link/3Tp7uxw #mmsm

Learning and sharing with the myeloma teams in China Just left a 1000 bed hospital dedicated solely to blood diseases. Continuing the global fight against myeloma. #mmsm

The outstanding Minnie lab at ucsf is looking for postdocs. It’s a great opportunity to work with a talented PI!

The #Tandem26 Pharmacy Track & APP Track are seeking speakers! Visit one of the links below to learn more & apply by this Thursday, July 10. 🧪 Pharmacy: surveymonkey.com/r/552FCXC 🩺 APP: surveymonkey.com/r/RVGYNSB

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study #mmsm #bmtsm Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma Journal of Clinical Oncology #mmsm #bmtsm ascopubs.org/doi/10.1200/JC…

Common Terminology Criteria for Adverse Events (CTCAE) has 26 categories for 837 terms, and 3,185 options when you account for Grade 1 to 5 🤯! I wanted to be able to interactively visualize CTCAE so I some wrote code 🧑‍💻 TheCodingDocs.com Take a look at --> thecodingdocs.com/clincal/ctcae